Xeris Biopharma Holdings, Inc. (XERS)
Market: NASD |
Currency: USD
Address: 180 North LaSalle Street
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Show more
📈 Xeris Biopharma Holdings, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$6.30
-
Upside/Downside from Analyst Target:
37.55%
-
Broker Call:
8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
25-50%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Xeris Biopharma Holdings, Inc.
| Date | Reported EPS |
|---|
| 2026-03-04 (estimated upcoming) | - |
| 2025-11-06 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-08-06 (estimated upcoming) | - |
| 2025-08-05 (estimated upcoming) | - |
| 2025-05-08 | -0.06 |
| 2025-05-07 | - |
| 2025-03-06 | -0.03 |
| 2025-03-03 | - |
| 2024-11-08 | -0.11 |
| 2024-08-08 | -0.1 |
| 2024-08-07 | -0.1 |
| 2024-05-09 | -0.14 |
| 2024-05-08 | -0.14 |
| 2024-03-06 | -0.1 |
| 2024-03-05 | -0.1 |
| 2023-11-09 | -0.09 |
| 2023-11-08 | -0.09 |
| 2023-08-08 | -0.14 |
| 2023-08-07 | -0.14 |
| 2023-05-09 | -0.12 |
| 2023-05-08 | -0.12 |
| 2023-03-08 | -0.1 |
| 2023-03-07 | -0.1 |
| 2022-11-09 | -0.16 |
| 2022-11-08 | -0.16 |
| 2022-08-10 | -0.19 |
| 2022-08-09 | -0.19 |
| 2022-05-11 | -0.25 |
| 2022-05-10 | -0.25 |
| 2022-03-10 | -0.42 |
| 2022-03-09 | -0.42 |
| 2021-11-10 | -0.39 |
| 2021-11-09 | -0.39 |
| 2021-08-05 | -0.41 |
| 2021-08-04 | -0.41 |
| 2021-05-13 | -0.3 |
| 2021-05-12 | -0.3 |
| 2021-03-09 | -0.41 |
| 2021-03-08 | -0.41 |
| 2020-11-09 | -0.35 |
| 2020-11-08 | -0.35 |
| 2020-08-10 | -0.63 |
| 2020-08-09 | -0.63 |
| 2020-05-07 | -0.89 |
| 2020-05-06 | -0.89 |
| 2020-03-11 | -1.23 |
| 2020-03-10 | -1.23 |
| 2019-11-06 | -1.22 |
| 2019-08-05 | -1.28 |
| 2019-05-08 | -1.07 |
| 2019-03-05 | -0.98 |
| 2018-11-06 | -0.71 |
| 2018-08-12 | -3.07 |
| 2018-06-20 | - |
📰 Related News & Research
No related articles found for "xeris biopharma".
